Clinical Trial Update: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL [Phase 2]

View source ↗

Summary

Phase 2 trial results for pembrolizumab after autologous stem cell transplant in Hodgkin lymphoma, diffuse large B-cell lymphoma, and peripheral T-cell lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-12-08